alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
ARMED SERVICES BOARD OF CONTRACT APPEALS Appeal of-- The Boeing Company Under Contract No. N00383-07-D-001J APPEARANCES FORTHE APPELLANT: ) ) ) ) )

APPEARANCES FORTHE GOVERNMENT: ASBCA No. 59611

Scott M. McCaleb, Esq. John R. Prairie, Esq. Jon W. Burd, Esq. Kara M. Sacilotto, Esq. Craig M. Smith, Esq.

Wiley Rein LLP Washington, DC Ronald J. Borro, Esq.

Navy ChiefTrial Attorney Anthony K. Hicks, Esq.

Trial Attorney ORDER OF DISMISSAL The dispute has been settled. The appeal is dismissed with prejudice. Dated: 4 January 2016

Administrative Judge Acting Chairman Armed Services Board ofContract Appeals I certify that the foregoing is a true copy ofthe Order ofDismissal ofthe Armed Services Board ofContractAppeals in ASBCA No. 59611, Appeal ofThe Boeing Company, rendered in conformance with the Board's Charter. Dated:

JEFFREY D. GARDIN Recorder, Armed Services Board ofContract Appeals
Exhibit






Exhibit 10.02
AMENDMENT
TO THE
NUSTAR EXCESS THRIFT PLAN


WHEREAS, NuStar Services Company LLC (“NuStar”) sponsors and maintains the NuStar Excess Thrift Plan (the “Plan”) for the benefit of eligible Employees; and 


WHEREAS, NuStar wishes to amend the Plan to permit the Employer to make special discretionary Employer contributions under the Plan to such Plan Participants and in such amounts as the Employer may determine from time to time in its sole and absolute discretion; and 


WHEREAS, NuStar has reserved the right to amend the Plan pursuant to Section 9.1 thereof.


NOW, THEREFORE, the Plan is hereby amended, effective as of January 1, 2017, as follows:


1.    Discretionary Employer Contributions.  The Plan is hereby amended by adding the following language as a new Section 6, and by renumbering the remaining sections of the Plan accordingly.  As amended, the newly added Section 6 of the Plan shall be and read in full as follows:


“SECTION 6.  DISCRETIONARY EMPLOYER CONTRIBUTIONS. 
In addition to the benefits provided for under the §415(c) Benefit Plan Component and the §417(a)(17) Benefit Plan Component described above, the Employer may make special Employer discretionary contribution credits from time to time to such Participants and in such amounts, as the Employer may, in its sole and absolute discretion, determine.  Such Employer discretionary contribution credits, if any, shall be subject to such vesting and forfeiture provisions as the Employer may determine.  Additionally, such Employer discretionary contribution credits, if any, shall be credited with earnings and/or losses pursuant to the provisions of Sections 7.2 and 7.3 hereof, and shall be paid in the form and at the time provided for under Section 7.5 hereof, subject to the 6-month delay provision of Section 7.6 hereof.”
2.    Defined Terms.  Unless otherwise defined herein, each of the capitalized terms used herein shall have the meaning given to such term in the Plan.









3.    No Further Amendments.  Except as otherwise amended hereby, the Plan shall remain in full force and effect in accordance with its terms.


IN WITNESS WHEREOF, NuStar has caused this Amendment to be signed on its behalf by its duly authorized representative this 11th day of January, 2017, to be effective as set forth above.


NUSTAR SERVICES COMPANY LLC






By:  /s/ Robert K. Grimes


Title:  VP Human Resources
69147.000002 EMF_US 63005540v1
§ 807.81 When a premarket notification submission is required. ( a ) Except as provided in paragraph (b) of this section, each person who is required to register his establishment pursuant to § 807.20 must submit a premarket notification submission to the Food and Drug Administration at least 90 days before he proposes to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of a device intended for human use which meets any of the following criteria: ( 1 ) The device is being introduced into commercial distribution for the first time; that is, the device is not of the same type as, or is not substantially equivalent to, ( i ) a device in commercial distribution before May 28, 1976, or
( ii ) a device introduced for commercial distribution after May 28, 1976, that has subsequently been reclassified into class I or II.
( 2 ) The device is being introduced into commercial distribution for the first time by a person required to register, whether or not the device meets the criteria in paragraph (a)(1) of this section.
( 3 ) The device is one that the person currently has in commercial distribution or is reintroducing into commercial distribution, but that is about to be significantly changed or modified in design, components, method of manufacture, or intended use. The following constitute significant changes or modifications that require a premarket notification: ( i ) A change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.
( ii ) A major change or modification in the intended use of the device.
( b ) ( 1 ) A premarket notification under this subpart is not required for a device for which: ( i ) A premarket approval application under section 515 of the act, or for which a petition to reclassify under section 513(f)(2) of the act, is pending before the Food and Drug Administration, or
( ii ) There is a predetermined change control plan (PCCP) cleared under section 515C of the act, provided that the change is consistent with the PCCP.
( 2 ) The appropriate FDA Center Director may determine that the submission and grant of a written request for an exception or alternative under § 801.128 or § 809.11 of this chapter satisfies the requirement in paragraph (a)(3) of this section.
( c ) In addition to complying with the requirements of this part, owners or operators of device establishments that manufacture radiation-emitting electronic products, as defined in § 1000.3 of this chapter, shall comply with the reporting requirements of part 1002 of this chapter.
[42 FR 42526, Aug. 23, 1977, as amended at 72 FR 73601, Dec. 28, 2007; 89 FR 18792, Mar. 15, 2024]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This  Schedule  contains  summary  financial   information  extracted  from  the
financial  statements contained in the body of the accompanying Form 10-K and is
qualified in its entirety by reference to such financial statements.
</LEGEND>
<MULTIPLIER>                                         1
       
<S>                                                  <C>
<PERIOD-TYPE>  Year
<FISCAL-YEAR-END>                                    Jun-30-1997
<PERIOD-END>   Jun-30-1997
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>  31,705
<ALLOWANCES>   0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION> 0
<TOTAL-ASSETS> 381,227
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             1,000
<OTHER-SE>                                           (22,198)
<TOTAL-LIABILITY-AND-EQUITY>                         381,227
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>  0
<OTHER-EXPENSES>                                     9,505
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      (9,505)
<INCOME-TAX>   (4,175)
<INCOME-CONTINUING>                                  (5,330)
<DISCONTINUED> 0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>   (5,330)
<EPS-PRIMARY>  0
<EPS-DILUTED>  0
        

</TABLE>
# C_2017347EN.01002501.xml

| 16.10.2017 | EN | Official Journal of the European Union | C 347/25 |
| --- | --- | --- | --- |

16.10.2017

EN

Official Journal of the European Union

C 347/25

---

Order of the General Court of 19 July 2017 — Yanukovych v Council

(Case T-347/14 INTP) (1)

1

((Procedure - Interpretation of an order))

(2017/C 347/33)

Language of the case: English

Parties

Parties

Applicant: Olga Stanislavivna Yanukovych, as heir of Viktor Viktorovych Yanukovych (Kiev, Ukraine) (represented by T. Beazley QC)

Applicant:

Defendant: Council of the European Union (represented by J.-P. Hix and P. Mahnič Bruni, acting as Agents)

Defendant:

Intervener in support of the defendant: European Commission (represented initially by S. Bartelt and D. Gauci, and subsequently by E. Paasivirta and J. Norris-Usher, acting as Agents)

Intervener in support of the defendant:

Re:

Re:

Application for interpretation of the order of 12 July 2016, Yanukovych v Council (T-347/14, EU:T:2016:433).

Yanukovych

Council

Operative part of the order

Operative part of the order

| 1. | Point 3 of the operative part of order of 12 July 2016, Yanukovych v Council (T-347/14), must be interpreted as meaning that, as regards the claim for annulment made in the application, it covers both costs incurred by Mr Viktor Viktorovych Yanukovych and those incurred by Mrs Olga Stanislavivna Yanukovych, as heir of Mr Viktorovych Yanukovych. |
| --- | --- |

1.

Point 3 of the operative part of order of 12 July 2016, Yanukovych v Council (T-347/14), must be interpreted as meaning that, as regards the claim for annulment made in the application, it covers both costs incurred by Mr Viktor Viktorovych Yanukovych and those incurred by Mrs Olga Stanislavivna Yanukovych, as heir of Mr Viktorovych Yanukovych.

| 2. | Mrs Stanislavivna Yanukovych, as heir of Mr Viktorovych Yanukovych, on the one hand, and the Council of the European Union, on the other hand, shall each bear their own costs relating to the interpretation proceedings. |
| --- | --- |

2.

Mrs Stanislavivna Yanukovych, as heir of Mr Viktorovych Yanukovych, on the one hand, and the Council of the European Union, on the other hand, shall each bear their own costs relating to the interpretation proceedings.

| 3. | The European Commission shall bear its own costs. |
| --- | --- |

3.

The European Commission shall bear its own costs.

| 4. | The original of this order shall be annexed to the original of the order interpreted, in the margin of which reference shall be made to this order. |
| --- | --- |

4.

The original of this order shall be annexed to the original of the order interpreted, in the margin of which reference shall be made to this order.

---

(1)  OJ C 253, 4.8.2014.

1

---
Michigan Supreme Court

Lansing, Michigan

Bridget M. McCormack, Chief Justice

Brian K. Zahra

David F. Viviano

Richard H. Bernstein

Elizabeth T. Clement

Megan K. Cavanagh

Elizabeth M. Welch, Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

 January 22, 2021

Order 

Clerk

January 29, 2021

156150(52)

JOSHUA WADE,

Plaintiff-Appellant,

SC: 156150

v COA: 330555

Ct of Claims: 15-000129-MZ

UNIVERSITY OF MICHIGAN,

Defendant-Appellee.

______________________________________/

On order of the Chief Justice, the joint motion of the Fair Housing Center of 

Southeast and Mid-Michigan, the Fair Housing Center of Southwest Michigan, and the 

Fair Housing Center of West Michigan to file a brief amicus curiae is GRANTED. The 

amicus brief submitted on January 22, 2021, is accepted for filing. .
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          AUG-31-1999
<PERIOD-START>                             SEP-01-1998
<PERIOD-END>                               AUG-31-1999
<CASH>                                          22,629
<SECURITIES>                                    11,088
<RECEIVABLES>                                6,426,385
<ALLOWANCES>                                   130,397
<INVENTORY>                                 18,801,015
<CURRENT-ASSETS>                            25,854,703
<PP&E>                                      16,845,961
<DEPRECIATION>                               9,635,739
<TOTAL-ASSETS>                              33,084,378
<CURRENT-LIABILITIES>                       17,153,968
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        53,038
<OTHER-SE>                                  12,520,235
<TOTAL-LIABILITY-AND-EQUITY>                33,084,378
<SALES>                                     59,555,595
<TOTAL-REVENUES>                            59,555,595
<CGS>                                       51,894,341
<TOTAL-COSTS>                               51,894,341
<OTHER-EXPENSES>                              (41,971)
<LOSS-PROVISION>                               130,397
<INTEREST-EXPENSE>                             832,539
<INCOME-PRETAX>                              1,264,727
<INCOME-TAX>                                   490,375
<INCOME-CONTINUING>                            774,352
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   774,352
<EPS-BASIC>                                        .15
<EPS-DILUTED>                                      .15


</TABLE>
[Nos. 37701-9-I; 37831-7-I.

Division One.

December 1, 1997.]

#### The State of Washington, *Respondent,*v. Dale R. Williams, *Appellant. In the Matter of the Personal Restraint of*Dale R. Williams, *Petitioner.*

Appeal from a judgment of the Superior Court for King County, No. 86-1-02410-3, Ricardo S. Martinez, J., entered August 29, 1995, together with a petition for relief from personal restraint. Judgment *affirmed*and petition *denied*by unpublished per curiam opinion.
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.61 Statement of identity. ( a ) The principal display panel of an over-the-counter drug in package form shall bear as one of its principal features a statement of the identity of the commodity.
( b ) Such statement of identity shall be in terms of the established name of the drug, if any there be, followed by an accurate statement of the general pharmacological category(ies) of the drug or the principal intended action(s) of the drug. In the case of an over-the-counter drug that is a mixture and that has no established name, this requirement shall be deemed to be satisfied by a prominent and conspicuous statement of the general pharmacological action(s) of the mixture or of its principal intended action(s) in terms that are meaningful to the layman. Such statements shall be placed in direct conjunction with the most prominent display of the proprietary name or designation and shall employ terms descriptive of general pharmacological category(ies) or principal intended action(s); for example, “antacid,” “analgesic,” “decongestant,” “antihistaminic,” etc. The indications for use shall be included in the directions for use of the drug, as required by section 502(f)(1) of the act and by the regulations in this part.
( c ) The statement of identity shall be presented in bold face type on the principal display panel, shall be in a size reasonably related to the most prominent printed matter on such panel, and shall be in lines generally parallel to the base on which the package rests as it is designed to be displayed.
§ 522.1465 Naltrexone. ( a ) *Specifications.* Each milliliter of solution contains 50 milligrams of naltrexone hydrochloride.
( b ) *Sponsor.* See 053923 in § 510.600(c) of this chapter.
( c ) *Conditions of use in elk and moose* — ( 1 ) *Amount.* 100 milligrams of naltrexone hydrochloride for each milligram of carfentanil citrate administered. One-quarter of the dose should be administered intravenously and three-quarters of the dose should be administered subcutaneously.
( 2 ) *Indications for use.* As an antagonist to carfentanil citrate immobilization in free-ranging or confined elk and moose (*Cervidae*).
( 3 ) *Limitations.* Do not use in domestic food-producing animals. Do not use in free-ranging animals for 45 days before or during hunting season. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[62 FR 5320, Feb. 5, 1997, as amended at 79 FR 16191, Mar. 25, 2014]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7776 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7776

 To amend the Boulder Canyon Project Act to authorize the Secretary of 
the Interior to expend amounts in the Colorado River Dam fund, and for 
                            other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 21, 2024

 Ms. Lee of Nevada (for herself, Mr. Amodei, Mr. Horsford, Ms. Titus, 
  Mr. Ciscomani, Mr. Gallego, Mr. Gosar, Mrs. Lesko, Mr. Stanton, and 
 Mrs. Napolitano) introduced the following bill; which was referred to 
                   the Committee on Natural Resources

_______________________________________________________________________

                                 A BILL

 
 To amend the Boulder Canyon Project Act to authorize the Secretary of 
the Interior to expend amounts in the Colorado River Dam fund, and for 
                            other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Help Hoover Dam Act''.

SEC. 2. AUTHORIZATION TO EXPEND AMOUNTS.

    Section 2 of the Act of December 21, 1928 (43 U.S.C. 617, et seq.; 
commonly known as the ``Boulder Canyon Project Act''), is amended by 
adding at the end the following:
    ``(f) The Secretary of the Interior is authorized to expend moneys 
in the fund, including moneys in account XXXR5656P1, that were and 
hereafter are recovered on a non-reimbursable basis, for any authorized 
activity, including operations, maintenance, investigation and cleanup 
actions, and capital improvements, within the Boulder Canyon Project at 
Hoover Dam or on land used for the construction and operation of the 
Hoover Dam, subject to the review and approval of the Boulder Canyon 
Project contractors as identified in the Hoover Power Allocation Act of 
2011 (Public Law 112-72).''.
                                 <all>
```
§ 74.1307 D&C Red No. 7. ( a ) *Identity.* ( 1 ) The color additive D&C Red No. 7 is principally the calcium salt of 3-hydroxy-4-[(4-methyl-2-sulfophenyl)azo]-2-naphthalenecarboxylic acid (CAS Reg. No. 5281-04-9). To manufacture the additive, 2-amino-5-methylbenzenesulfonic acid is diazotized with hydrochloric acid and sodium nitrite. The diazo compound is coupled in alkaline medium with 3-hydroxy-2-naphthalenecarboxylic acid and the resulting dye converted to the calcium salt with calcium chloride.
( 2 ) Color additive mixtures for drug use made with D&C Red No. 7 may contain only those diluents that are suitable and that are listed in part 73 of this chapter as safe for use in color additive mixtures for coloring drugs.
( b ) *Specifications.* The color additive D&C Red No. 7 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by current good manufacturing practice: Sum of volatile matter (at 135 °C) and chlorides and sulfates (calculated as sodium salts), not more than 10 percent. 1-[(4-methylphenyl)azo]-2-naphthalenol, not more than 0.015 percent. 2-Amino-5-methylbenzenesulfonic acid, calcium salt, not more than 0.2 percent. 3-Hydroxy-2-naphthalenecarboxylic acid, calcium salt, not more than 0.4 percent. 3-Hydroxy-4-[(4-methylphenyl)azo]-2-naphthalenecarboxylic acid, calcium salt, not more than 0.5 percent. *p*-Toluidine, not more than 15 parts per million. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 90 percent.
( c ) *Uses and restrictions.* The color additive D&C Red No. 7 may be safely used for coloring drugs such that the combined total of D&C Red No. 6 and D&C Red No. 7 does not exceed 5 milligrams per daily dose of the drug.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Red No. 7 shall be certified in accordance with regulations in part 80 of this chapter.
[47 FR 57687, Dec. 28, 1982, as amended at 77 FR 39923, July 6, 2012]